Vestmark Advisory Solutions Inc. Buys 24,262 Shares of Illumina, Inc. $ILMN

Vestmark Advisory Solutions Inc. boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 101.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,092 shares of the life sciences company’s stock after acquiring an additional 24,262 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Illumina were worth $4,588,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Andra AP fonden grew its holdings in Illumina by 426.3% in the 2nd quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock worth $9,779,000 after acquiring an additional 83,017 shares during the last quarter. Resona Asset Management Co. Ltd. raised its holdings in shares of Illumina by 7.0% during the second quarter. Resona Asset Management Co. Ltd. now owns 50,851 shares of the life sciences company’s stock valued at $4,848,000 after acquiring an additional 3,309 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Illumina by 24.9% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 93,807 shares of the life sciences company’s stock valued at $8,950,000 after purchasing an additional 18,672 shares during the period. NewSquare Capital LLC raised its holdings in Illumina by 604.9% in the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after purchasing an additional 369 shares in the last quarter. Finally, Bryce Point Capital LLC purchased a new stake in Illumina in the second quarter worth about $854,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Illumina

In other Illumina news, Director Scott Gottlieb bought 500 shares of Illumina stock in a transaction on Monday, November 3rd. The stock was acquired at an average cost of $122.13 per share, with a total value of $61,065.00. Following the completion of the acquisition, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.60% of the company’s stock.

Illumina Trading Up 0.7%

Illumina stock opened at $121.90 on Friday. The business’s fifty day moving average is $100.51 and its 200 day moving average is $94.30. Illumina, Inc. has a one year low of $68.70 and a one year high of $154.43. The stock has a market capitalization of $18.63 billion, a PE ratio of 15.43, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.18. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm’s quarterly revenue was up .4% on a year-over-year basis. During the same quarter last year, the company posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ILMN shares. Morgan Stanley upped their price target on Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Monday, August 4th. Scotiabank lowered shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price target for the company. in a research note on Friday, July 11th. Cowen reissued a “hold” rating on shares of Illumina in a research report on Friday, October 31st. Daiwa Capital Markets cut shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective on the stock. in a report on Tuesday, August 12th. Finally, Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday. Five research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $115.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.